Creating a new therapy for multiple sclerosis
Development of a novel accurate therapy for multiple sclerosis
This study is working on a new, personalized treatment for multiple sclerosis that aims to target specific parts of the disease, which could help improve your symptoms and overall quality of life better than current medications.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Autoimmunity Biologic Solutions, INC. NIH-funded |
| Lab location | 1 site (Galveston, UNITED STATES) |
| Project ID | NIH-10687987 on NIH RePORTER |
What this research studies
This research focuses on developing a personalized therapy for multiple sclerosis (MS), a debilitating autoimmune disease that affects the central nervous system. The approach aims to target specific molecular mechanisms involved in MS, particularly the role of the soluble form of the Interleukin 7 Receptor (sIL7R), which is linked to disease severity. By correcting the abnormal splicing of pre-mRNA that leads to elevated sIL7R levels, the therapy seeks to provide a more effective and well-tolerated treatment option compared to current immunosuppressive therapies. Patients may benefit from a therapy that specifically addresses their unique disease mechanisms, potentially improving their quality of life.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with multiple sclerosis who may benefit from targeted therapies that address specific disease mechanisms.
Not a fit: Patients with forms of multiple sclerosis that do not involve the specific molecular mechanisms targeted by this therapy may not receive benefit.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and safer treatment for multiple sclerosis, reducing the need for immunosuppressive therapies.
How similar studies have performed: While there has been significant research into various therapies for multiple sclerosis, this specific approach targeting sIL7R represents a novel strategy that has not been widely tested.
Where this research is happening
Galveston, UNITED STATES
- Autoimmunity Biologic Solutions, INC. — Galveston, United States (Active)
Researchers
- Principal investigator: Galarza-Munoz, Gaddiel — Autoimmunity Biologic Solutions, INC.
- Study coordinator: Galarza-Munoz, Gaddiel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.